key: cord-0870577-xqrwtb8e
authors: Thieme, Constantin J.; Anft, Moritz; Paniskaki, Krystallenia; Blazquez-Navarro, Arturo; Doevelaar, Adrian; Seibert, Felix S.; Hoelzer, Bodo; Konik, Margarethe Justine; Brenner, Thorsten; Tempfer, Clemens; Watzl, Carsten; Meister, Toni L.; Pfaender, Stephanie; Steinmann, Eike; Dolff, Sebastian; Dittmer, Ulf; Westhoff, Timm H.; Witzke, Oliver; Stervbo, Ulrik; Roch, Toralf; Babel, Nina
title: Robust T cell response towards spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients
date: 2020-08-29
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2020.100092
sha: aa464684091c01220b73efef9f03175f76f52df4
doc_id: 870577
cord_uid: xqrwtb8e

T cell immunity towards SARS-CoV-2 spike (S), membrane (M), and nucleocapsid (N)-proteins might define COVID-19 severity. Therefore, we compare the SARS-CoV-2-reactive T cell responses in moderate, severe, and critical COVID-19 patients and unexposed donors. Overlapping peptide pools of all three proteins induce SARS-CoV-2-reactive T cell response with dominance of CD4+ over CD8+ T cells and demonstrate interindividual immunity against the three proteins. M-protein induces the highest frequencies of CD4+ T cells, suggesting its relevance for diagnosis and vaccination. Importantly, T cell response of critical COVID-19 patients is robust and comparable or even superior to non-critical patients. Virus clearance and COVID-19 survival are not associated with either SARS-CoV-2 T cell kinetics or magnitude of T cell responses, respectively. Thus, our data disprove the hypothesis of insufficient SARS-CoV-2-reactive immunity in critical COVID-19. Conversely, it indicates that activation of differentiated memory effector T cells could cause hyper-reactivity and immunopathogenesis in critical patients.

Clearance of viral pathogens requires an effective T cell response directed against protein antigens expressed by the virus. 1 The T cell response against the severe acute respiratory syndrome-related coronavirus (SARS-CoV)-2 virus, which causes the ongoing pandemic, is presumably initiated by respiratory professional antigen presenting cells (APC) that can engulf viral antigens as shown for the 2002/03 SARS-CoV. 2 As the production of type-Iinterferons, which can directly and indirectly induce and enhance antiviral effector T cell responses, 3 is suppressed in SARS-CoV-2 infection, especially in severe cases, 4, 5 one could hypothesize that the reduced type-I-interferon response results in an impaired T cell immunity in severe SARS-CoV-2 infection, as observed in SARS-CoV-1 infection. 6 Activated T cells can migrate to the site of infection, where they facilitate viral clearance. On the other hand, antigen-specific T cells can contribute to immune pathogenesis. There is mounting evidence that the latter is the major reason for critical COVID-19 disease manifestations, 7, 8 as evidenced also by the recent findings of successful treatment of COVID-19 patients with immunosuppressive dexamethasone. 9 The SARS-CoV-2 contains four structural proteins: the spike glycoprotein (S), the envelope (E) protein, the membrane (M) protein and the nucleocapsid (N) protein. 10 The S-protein mediates host cell entry by binding to the angiotensin-converting enzyme 2 (ACE2). 11 Due to its surface-exposure and crucial role for infecting host cells, the S-protein is an attractive therapeutic target, for instance for antibodies that block the S/ACE2 interaction. In fact, it was shown that patients recovered from COVID-19 developed virus neutralizing anti-S immunoglobulin (Ig) titers. 12 Given the requirement for T cell help in generation of high affinity IgG antibodies, this finding indicates that S-protein-reactive T cell immunity was formed in those patients. 13, 14 Accordingly, very recent studies identified SARS-CoV-2 J o u r n a l P r e -p r o o f S-protein reactive T cell responses in patients suffering from moderate, severe, and critical COVID-19. 8, 15 Furthermore, it was shown that the amount of SARS-CoV-2 S-protein reactive CD4 + T cells increased with disease progression. 16 Besides the S-protein, also the N-and Mproteins were suggested as potential targets for diagnostic and prophylactic approaches. 7, 10 In fact, B cell responses against the N-protein seemed to be the first to arise 4-8 days after symptom onset for the 2002/03 SARS-CoV infection, 17, 18 which indicates that also N-reactive T cell response are prevalent during this timeframe. The M-protein is the most abundant surface protein of SARS-CoV virions, suggesting a high antigenicity. 19 Grifoni et al. provided data on T cell responses towards a diverse set of SARS-CoV-2 epitopes in recovered COVID-19 patients. 20 However, currently there is no analysis of the T cell reactivity towards these antigens in hospitalized patients and no association with disease severity available. These data are important to understand possible immunopathogenic effects provided by T cells reactive to certain SARS-CoV-2 proteins. A dominant T cell response towards viral antigens has been associated with immunopathogenesis for example in patients with hemorrhagic fever following dengue virus infection. 21 Observation of similar mechanisms in COVID-19 could possibly influence vaccination and treatment strategies profoundly. It has been shown, that studying T cell responses might be more reliable than antibody testing in Swedish and French cohorts. 22, 23 Information on early T cell responses in critical COVID-19 patients in comparison to non-critical is currently lacking, but is important to define strategies addressing epidemiological questions. Another unresolved question is the influence of the magnitude of the T cell response for the clinical disease course.

For these reasons, we identified, characterized, and compared S-, M-, and N-reactive T cell responses in COVID-19 patients with different clinical manifestation during the acute disease phase and at recovery. J o u r n a l P r e -p r o o f

We analyzed 65 blood samples drawn at different time points after hospital admission of a cohort of 28 COVID-19 patients with moderate (32 samples), severe (16 samples), and critical (17 samples) disease manifestation (Table 1 and Table S1 ). The patients were grouped into the respective category according to their worst manifestation using the German Robert-Koch-Institute symptom classification as previously described. 8 (Table S2) .

By stimulation with S-, M-, or N-overlapping peptide pools (OPP), we could show that all three proteins have the capacity to induce SARS-CoV-2-reactive CD4 + and CD8 + T cells (Fig.   1a ). To this end, we used pools of mainly 15mer peptide with 11 amino acid overlaps spanning the whole N-and M-protein or in-silico predicted immunodominant sequence domains of S-protein (Fig. S1 ). Large overlapping peptide pools have been shown to allow monitoring of antigen-specific T cell responses independent of HLA-type. 25 This approach is J o u r n a l P r e -p r o o f therefore time and cost efficient and allows monitoring of T cell reactivity in bigger cohorts.

After 16h of stimulation, antigen-reactive T cell responses were detected by intracellular staining using flow cytometry. The gating strategy is presented in Fig. S2 . Activation markers CD154 and CD137 in CD4 + T cells and CD137 in combination of production of any of interleukin (IL)-2, interferon γ (IFNγ), tumor necrosis factor α (TNFα), and/or granzyme B (GrzB) in CD8 + T cells (termed CD137 + cytokine + CD8 + T cells) were used to define SARS-CoV-2 reactive T cells. We regarded responses as detectable if the frequency in the specifically stimulated sample exceeded the unstimulated DMSO control 3 times (stimulation index >3).

The presented frequencies show values in the stimulated samples after subtraction of the unstimulated control ( Fig. 1 and Fig. S3 ).

Considering response rate per patient population, CD4 + T cell and CD8 + T cell responses were detectable in at least one sample in 27 (96.4%) and 21 (75%) of COVID-19 patients, respectively ( Fig. 1b-d) . Considering response rate per sample, we detected a CD4 + T cell response in 56 and a CD8 + T cell response in 33 out of 65 patient samples against at least one of the SARS-CoV-2 proteins (Fig. S3a-c) . However, none of the proteins induced CD4 + or CD8 + T cell responses in all 56 and 33 positive samples, respectively. Within the 56 responding samples, M-protein OPP induced a detectable CD4 + T cell response in the highest number of samples (M=45, N=36, S=42), whereas for the 33 responding samples within CD8 + subsets, the S-protein OPP was dominant (M=13, S=26, N=14) ( Fig. S3a-c) . Therefore, testing a single protein-OPP would underestimate T cell immunity in at least 20% of patients.

Although the immunogenicity of the three proteins and its role for the clinical course require follow up investigations, our data advocate that measuring T cell responses induced by all three proteins is of high relevance when studying SARS-CoV-2-reactive T cells, especially in the early phase of disease. In accordance to other studies, 15, 20 SARS-Cov-2 reactive T cells J o u r n a l P r e -p r o o f were detectable also in samples of unexposed donors, frozen before the outbreak of COVID-19. We measured detectable CD4 + T cells in 4 and CD8 + T cells in 3 of 10 unexposed donors ( Fig. 1 b-d) . Overall, the level of T cell responses was lower in unexposed donors, confirming the specificity of SARS-CoV-2 peptide stimulation in COVID-19 patients.

Comparing the magnitude of response against the three proteins, we found that the M-protein OPP induced the highest frequencies of reactive CD4 + T cells, similarly to the number of detectable CD4 + T cell responses described above (Fig. 2a) . Compared to the Sand N-reactive CD4 + T cells, we found a consistent trend of higher frequencies of M-reactive CD4 + T cells expressing cytokines and effector molecules such as IL-2, IFNγ, TNFα, and GrzB. N-protein induced the lowest responses in comparison to the other proteins ( Fig. 2b-f ).

Interestingly, the pattern observed for S-, N-, and M-protein reactivity of CD4 + T cells were not found in CD8 + T cells (Fig. 2j-o) . In fact, a tendency of higher frequencies of S-or Nprotein reactive CD8 + T cells compared to M-protein was observed, but without reaching statistical significance after correction for multiple testing. Analyzing a possible correlation in frequencies of T cells reactive to S-, N-, and M-proteins, we did not observe a strong correlation in CD4 + as well as CD8 + T cell restricted immunity (Fig 2g- i, p-r).

The exact role of SARS-CoV-2-reactive T cell immunity for COVID-19 progression is currently unknown. We therefore investigated differences in the T cell immunity between moderate, J o u r n a l P r e -p r o o f severe and critical COVID-19 patients. A defective switch between innate and adaptive immunity has been described to differentiate patients with favorable and unfavorable outcome after SARS-CoV infection in previous studies. 26 Surprisingly, and in contrast to the endemic SARS-CoV infection, we detected a comparable or even slightly higher magnitude of CD4 + and CD8 + T cells reactive to S-, M-, and N-proteins in critical COVID-19 as compared to moderate and severe cases (Fig. 3) .

Examining a limited number of subjectively selected functions of virus-reactive T cells may generate distorted and incomplete interpretation of the function and phenotype of these cells. 27 Polyfunctional T cells, that express more than one cytokine or effector molecule, have been described as a hallmark of protective immunity in viral infections. [27] [28] [29] [30] Addressing this point, we analyzed the IFNγ, TNFα, IL-2, and IL-4 cytokines as well as the effector molecule GrzB expression in parallel to differentiation stage phenotyping. Of interest, not only the quantity but also the functionality of T cell immunity was similar, or even higher in patients with critical COVID-19 severity compared to moderate and severe cases ( 

An immunodominance of T cell responses towards certain peptides has been associated with immunopathology in flaviviridae. 21, [33] [34] [35] However, the relative composition of T cell responses against S-, M-and N-protein in COVID-19 patient samples was mostly uniform across the different disease severities (Fig. S5 ).

In line with data showing an association between polyfunctionality and the stage of phenotypic differentiation, 27 we observed similar frequencies of CD4 + and CD8 + T cells with effector memory (T EM )/T EMRA phenotype in critical COVID-19 samples compared to moderate and severe samples (Fig S6a-b) . Importantly, the presence of S-, N-, and M-reactive T cells with an advanced differentiation phenotype early after diagnosis in our study indicates preexisting cellular immunity as demonstrated by detection of SARS-CoV-2-crossreactive T cells in unexposed donors in our and other studies. 15, 20 Of note, few unexposed donors also showed detectable polyfunctional T cells (Fig. 1b) . The memory composition of SARS-CoV-2 reactive T cells in unexposed donors largely resembled the COVID-19 patients, with the exception of fewer CD4 + and CD8 + T EM and more central memory (T CM ) and naïve (T NAIVE ) cells ( Fig. S6a-b ).

and what the basis for a critical disease manifestation in certain individuals is. To investigate a possible involvement of impaired/insufficient adaptive immune responses, we stratified our patients according to their virus clearance status. Patients that were discharged from the hospital, or had a minimum of 2 negative SARS-CoV-2 RNA PCR samples without a positive sample thereafter, were categorized as cleared. Patients that were not discharged and had J o u r n a l P r e -p r o o f repetitive positive PCR results were grouped as uncleared. All patients from whom this information or follow-up samples were not available were excluded from this analysis.

Consequently, we could include 11 patients in the cleared cohort and 7 patients in the uncleared cohort. Their clinical characteristics are described in Table S3 . In the cleared group, we analyzed an initial blood sample before viral clearance and a follow up sample after clearance. In the uncleared group, the first and the last available samples were obtained. There were no significant differences in sampling time related to the date of first positive PCR and to the hospital admission as well as in the time between the initial sample and the follow up sample between the cleared and uncleared cohort (Table S3) . We observed no significant differences regarding detectable T cell responses between the two cohorts ( Fig. 4a) . Additionally, the frequencies of SARS-CoV-2 protein reactive CD4 + and CD8 + T cells, the frequencies of polyfunctional CD4 + T cells as well as the ratio of initial and follow up samples did not differ between the groups ( Fig. 4b-i ). Patients that did not clear the virus achieved a comparable magnitude of SARS-CoV-2 reactive T cell immunity as compared to the clearing patients already at the initial time point. Furthermore, we measured higher titers of neutralizing antibodies in patients that did not successfully clear the virus compared to patients that cleared the virus (Fig. S7 ).

In line with the viral clearance data, we did not find any changes in SARS-CoV-2-reactive T cells associated with recovery from COVID-19. Comparisons of clinical characteristics and sample timing are summarized in Table S4 . The magnitude of S-, M-, and N-reactive T cells measured at the time of critical COVID-19 did not show significant differences in comparison to the corresponding measurements performed directly after patients´ recovery (Fig. 5) . Of interest, the T cell data of recovering critical patients were comparable with the magnitude and functionality of S-, M-, and N-reactive T cell immunity measured at the initial visit in J o u r n a l P r e -p r o o f critical patients with lethal outcome (Fig. 5b-i) suggesting that other cell subsets or cell subsets located at another site such as the infected organ are responsible for antiviral control and disease manifestation. Critical patients appear to have a generally higher level of SARS-CoV-2 reactive T cells as compared to the non-critical controls, but it has to be kept in mind that the critical patients are probably later in their infectious course (Table S4 ) with more time for T cell proliferation. Accordingly, the differences between critical and moderate patients decrease in follow up (Fig. 5 ).

Our data provide a comprehensive characterization of the T cell response against S-, M-and findings and results of two other studies can be explained by different methodological protocols and different populations analyzed in the studies. Thus, our study analyzed patients with different COVID-19 severity, while convalescent patients or patients with acute respiratory distress syndrome were analyzed in studies by Grifoni et al. and Weiskopf et al., respectively. 16, 20 Furthermore, instead of using the two activation markers CD137 and CD69

for the definition of antigen-specific CD8 + T cells, we used activation marker CD137 together with at least one cytokine. In addition, overlapping peptide pools containing 15-mers were applied in our study for T cell stimulation, whereas Weiskopf et al. and Grifoni et al. used peptide pools consisting mainly 9-11 amino acid long peptides for optimal stimulation of CD8 + T cells as identified by a bioinformatics epitope prediction approach. 36 In fact, 9-to-11mer are described to be optimal for being presented via MHC-class I molecules for CD8 + T cell activation, and there are some concerns that CD8 + T cell responses can be underestimated using 15-mer peptides. However, previous studies by other and our groups 37-39 demonstrated 15-mer as non-inferior T cell stimulation source and appropriate experimental set up can avoid underestimation. 37 Induction of CD4 + and CD8 + T cell responses in unexposed donors in our cohort is comparable to previous investigations and can probably be attributed to cross-reactivity towards common-cold coronaviruses. 15, 40 A prolonged positivity of SARS-CoV-2 RT-PCR has been observed for up to several weeks after infection. 41 Factors that influence this finding in certain individuals as well as the infectiousness of the detected virus are yet to be investigated. Seroconversion, as a sign of the development of adaptive immunity, does not implicate PCR negativity. 42 Similarly, we did not find differences in the T cell responses of patients that cleared the virus to patients that did not clear. Interestingly, neutralizing antibodies were higher in the serum of patients Although the direct antiviral capacity has to be proven in future studies, polyfunctional T cells are commonly regarded as a parameter of protective immunity. 27, 29, 30, 44 To this end, the presence of IFNγ and TNFα coproducing CD4 + and CD8 + T cells indicating an effector/memory phenotype and long-term protection was also shown for the 2002/03 SARS-CoV. 45, 46 However, they can also provide immune damage contributing to immunopathogenesis, 47 and the correlation of IFNγ-induced IP10, T cell proliferation and COVID-19 progression observed in a recent study might underline this hypothesis. 43 In this context, our finding of an advanced differentiation stage of SARS-CoV-2-reactive T cells found at early time points and in unexposed donors raises the question about the beneficial J o u r n a l P r e -p r o o f effect of pre-existing immunity for the course of infection. One could speculate that even though it appears to be generally protective, pre-existing SARS-CoV-2 reactive T cells with effector phenotype, which are cross-reactive with common cold corona viruses, 15 can lead to hyperactive response and immunopathogenesis in severe infection. It has been observed that preformed antigen-specific T cell skewed towards certain peptides due to previous infection with a different serotype can cause immunopathology in flaviviridae infection. 21, [33] [34] [35] It is therefore important to note that we did not find such skewed response in the critical patients as compared to moderate cases; however, a more detailed approach using individual peptides might be beneficial in order to study this question more closely in the future.

Another important finding is the lack of association between COVID-19 recovery and SARS- 

Our study has some limitations. Thus, the exact time point of infection in our cohort, as described above, is not known, and the slightly higher T cell response detected in critical patients might reflect a longer disease course in the critical cohort. Therefore, further prospective studies considering a longer follow up in non-critical patients enabling a better sampling time match between the groups would be required. Furthermore, only three SARS- See also Figure S1 , S2, S3, and Table S2 . See also Figure S1 , S2, S4, S5, S6, and Table S1.

Analysis of T cell responses of patients that cleared SARS-CoV-2 (n=11) and patients that did not clear SARS-CoV-2 according to RT-PCR and were not discharged from the hospital during the observation period (uncleared, n=7). In the cleared group, a sample before and after J o u r n a l P r e -p r o o f viral clearance was analyzed (initial and follow up sample, respectively). In the uncleared group, the first (initial) and the last (follow up) available sample were analyzed. Peripheral blood mononuclear cells were stimulated for 16h with S-, M-, or N-protein overlapping peptide pools and analyzed by flow cytometry. The gating strategy to identify SARS-CoV-2 S-, M-, or N-protein reactive T cells is presented in Fig. S2 . Fig. 2 and 3 , the mean frequency was calculated of all measured samples of an individual patient. For Fig. 4 and S7, we included patients that were discharged from the hospital or had a minimum of 2 negative SARS-CoV-2 RNA PCR samples without a positive sample thereafter in the cleared group. The uncleared group consisted of patients that were not discharged and had repetitive positive PCR results. All patients from whom this information or follow-up samples were not available were excluded from this analysis. Fig. 5 shows a more detailed analysis of critical patients (n=11). A first sample was collected during critical COVID-19 on ICU in all presented patients. Of patients with critical disease who survived, we collected a second sample at the day of the planned discharge from the intensive care unit (recovered critical group) (n=5). Samples of critically ill patients who deceased later on from the disease were categorized as deceased critical (n=6). One patient categorized as critical only had a short stay on ICU and was not included in this analysis. For moderate and severely ill patients, the initial and the last available samples were used for the non-critical control group. values were set to zero. Stimulation index (SI) was calculated by dividing the measured T cell subset response by the respective response in the DMSO control. If the DMSO control was negative, the minimum value across that subset was used for calculation. SI below 1 was set to 1. SI above 3 was considered detectable response. Relative changes of the follow up sample compared to the initial samples were calculated by dividing the frequency of the respective subset in the follow up sample by the frequency in the initial sample. If the initial sample was 0, the minimum value across that subset was used for calculation. If the value was below 0.01, it was set to 0.01. Multifunctional T cells were analyzed using Boolean gating of IL2, IL4, IFNγ, TNFα, and GrzB producing T cells in combination with CD154 for CD4 + and CD137 for CD8 + T cells. Statistical analysis was performed using R, version 3.6.2 50 and GraphPad Prism v7, which was also used for graphical representation. Venn diagrams were prepared using Venny v2.1 51 .

Non-parametric statistical tests were used where applicable. 

Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice

Middle East respiratory syndrome and severe acute respiratory syndrome

Regulation of antiviral T cell responses by type I interferons

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

The trinity of COVID-19: immunity, inflammation and intervention

A possible role of immunopathogenesis in COVID-19 progression

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Severe Acute Respiratory Syndrome Coronavirus 2−Specific An_body Responses in Coronavirus Disease

Selective CD4+ T Cell Help for Antibody Responses to a Large Viral Pathogen: Deterministic Linkage of Specificities

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients

Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers

The M Protein of SARS-CoV: Basic Structural and Immunological Properties

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Immunodominant T-cell responses to dengue virus NS3 are associated with DHF

Robust T cell immunity in convalescent individuals with asymptomatic or mild

Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion

Clinical Characteristics of Coronavirus Disease 2019 in China

T-cell epitope mapping by flow cytometry

Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome

Polyfunctional T cell responses are a hallmark of HIV-2 infection

The Immunobiology of SARS

Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants

Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV

New insights into the immunopathology and control of dengue virus infection

T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other

Cell Responses in Dengue Hemorrhagic Fever: Are Cross-Reactive T Cells Suboptimal?

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose?

Detection of antigen-specific T cells by cytokine flow cytometry: the use of whole blood may underestimate frequencies

Preferential expansion of human virusspecific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4+ T cells

SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses

Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region

A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis

Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

Memory CD8 T-Cell Differentiation during Viral Infection

Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection

BK polyomavirus infection and nephropathy: the virus-immune system interplay

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Oliveros JC. Venny. An interactive tool for comparing lists with Venn's diagrams

We feel deep gratitude to the patients who donated their blood samples and clinical data for this project. We would like to acknowledge the excellent technical assistance as well as the expertise of the immune diagnostic laboratory (Sarah Skrzypczyk, Eva Kohut, Julia Kurek, Jan Zapka) of the Center for Translational Medicine at Marien Hospital Herne. This work was supported by grants of Mercator Foundation, the BMBF e:KID (01ZX1612A), and BMBF NoChro (FKZ 13GW0338B).